HK1215870A1 - 種抗 的單克隆抗體及其獲得方法 - Google Patents

種抗 的單克隆抗體及其獲得方法

Info

Publication number
HK1215870A1
HK1215870A1 HK16103809.7A HK16103809A HK1215870A1 HK 1215870 A1 HK1215870 A1 HK 1215870A1 HK 16103809 A HK16103809 A HK 16103809A HK 1215870 A1 HK1215870 A1 HK 1215870A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
Prior art date
Application number
HK16103809.7A
Other languages
English (en)
Inventor
周海平林曉敏周俊杰裴爽昝琰璐汪瑞王浛白義白先宏
Original Assignee
北京東方百泰生物科技有限公司 室
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京東方百泰生物科技有限公司 室 filed Critical 北京東方百泰生物科技有限公司 室
Publication of HK1215870A1 publication Critical patent/HK1215870A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
HK16103809.7A 2015-06-09 2016-04-05 種抗 的單克隆抗體及其獲得方法 HK1215870A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510312910.8A CN105061597B (zh) 2015-06-09 2015-06-09 一种抗pd-1的单克隆抗体及其获得方法

Publications (1)

Publication Number Publication Date
HK1215870A1 true HK1215870A1 (zh) 2016-09-23

Family

ID=54491146

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103809.7A HK1215870A1 (zh) 2015-06-09 2016-04-05 種抗 的單克隆抗體及其獲得方法

Country Status (15)

Country Link
US (1) US20170240644A1 (zh)
EP (2) EP3176182A4 (zh)
JP (1) JP6588534B2 (zh)
KR (1) KR101876689B1 (zh)
CN (1) CN105061597B (zh)
AR (1) AR105619A1 (zh)
AU (1) AU2015398193B2 (zh)
CA (1) CA2972833C (zh)
EA (1) EA036779B1 (zh)
HK (1) HK1215870A1 (zh)
MX (1) MX2017008662A (zh)
NZ (1) NZ728874A (zh)
SG (1) SG11201705252UA (zh)
TW (1) TWI659969B (zh)
WO (1) WO2016197497A1 (zh)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
SG10201913303XA (en) 2015-07-13 2020-03-30 Cytomx Therapeutics Inc Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
JP7032311B2 (ja) 2015-07-16 2022-03-08 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用してがんを処置するための新規手法
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
WO2017058859A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
HRP20220436T1 (hr) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Protutijela koja se specifično vežu na pd-1 i njihove uporabe
CN105566496B (zh) * 2015-11-26 2019-04-02 大庆东竺明生物技术有限公司 阻断人程序性死亡因子1(pd-1)功能的单克隆抗体及其编码基因和应用
CN107286242B (zh) 2016-04-01 2019-03-22 中山康方生物医药有限公司 抗pd-1的单克隆抗体
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
CN107523548A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的t细胞及其用途
CN106046162B (zh) * 2016-06-21 2019-04-02 大庆东竺明生物技术有限公司 抗人程序性死亡因子1（pd-1）单克隆抗体的制备及应用
CN107814845B (zh) * 2016-09-14 2021-02-09 浙江特瑞思药业股份有限公司 新的抗pd-1纳米抗体及其应用
CN109952316A (zh) 2016-09-14 2019-06-28 北京韩美药品有限公司 一种能够特异性地结合pd-1的抗体及其功能片段
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
CN114456269A (zh) * 2016-09-21 2022-05-10 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
WO2018127709A1 (en) * 2017-01-06 2018-07-12 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
CA3049047A1 (en) * 2017-01-20 2018-07-26 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-1 antibodies and uses thereof
CN108341871A (zh) * 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 抗pd-1单克隆抗体及其制备方法和应用
CN106928348B (zh) * 2017-03-06 2020-08-21 哈尔滨医科大学 一种调控人体固有免疫的全人源单克隆抗体及其制备方法和应用
CN106939049B (zh) 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
CA3060935A1 (en) * 2017-05-01 2018-11-08 The Children's Medical Center Coporation Methods and compositions relating to anti-pd1 antibody reagents
CN107082813A (zh) * 2017-05-17 2017-08-22 董克海 靶向pd‑1的嵌合抗原受体分子及其应用
JP2020532991A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド プログラム細胞死タンパク質１に対する抗体
CN107446048B (zh) * 2017-09-13 2021-03-30 北京韩美药品有限公司 一种能够特异性地结合pd-1的抗体及其功能片段
CN118667027A (zh) 2017-11-13 2024-09-20 克雷森多生物制剂有限公司 结合至cd137和psma的分子
CN109467603B (zh) * 2017-11-14 2020-02-21 拜西欧斯（北京）生物技术有限公司 抗pd-1抗体及其制备方法和应用
CN108218988B (zh) * 2017-11-29 2019-10-11 广西医科大学 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用
CN108218989B (zh) * 2017-11-29 2020-08-18 广西医科大学 抗PD-1的纳米抗体PD-1/Nb18及其制备方法与应用
JP2021506976A (ja) * 2017-12-18 2021-02-22 ディストリビューテッド バイオ， インコーポレイテッド 根本的に多様なヒト抗体ライブラリー
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
WO2019179396A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-pd-1 antibodies
CN113195525A (zh) * 2018-06-29 2021-07-30 国民大学校产学协力团 对pd-1具有提高的结合亲和力的pd-l1变体
WO2020063823A1 (en) * 2018-09-27 2020-04-02 Zai Lab (Shanghai) Co., Ltd. Anti-pd-1 antibodies and uses thereof
CN112805302B (zh) * 2018-10-10 2023-01-31 深圳华大生命科学研究院 抗BCMA单链抗体scFv及其制备方法和应用
CA3131691A1 (en) * 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CN110095612B (zh) * 2019-04-12 2022-05-10 河北仁博科技有限公司 一种基于spr快速筛选单克隆抗体的方法
CN110194798A (zh) * 2019-05-31 2019-09-03 杭州科兴生物科技有限公司 抗pd-l1单克隆抗体、片段及其医药用途
CN117447596A (zh) * 2019-06-30 2024-01-26 福州创方医药科技有限公司 一种靶向pd-1的单克隆抗体及其应用
CN112225809B (zh) * 2019-06-30 2023-09-05 福州创方医药科技有限公司 一种靶向pd-1的单克隆抗体及其应用
KR20220030956A (ko) 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
JP2022550243A (ja) * 2019-09-30 2022-12-01 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ｐｄ－１抗体及びその使用
CN111018989B (zh) * 2019-12-16 2021-03-23 郑州大学 一种抗pd-l1单克隆抗体以及在制备抗癌药物方面的应用
CN113336847B (zh) * 2021-02-03 2022-08-23 上海莱馥医疗科技有限公司 一种抗pd-1抗体
CN113150154B (zh) * 2021-04-15 2022-05-10 博奥信生物技术（南京）有限公司 抗人pdl1单克隆抗体及其用途
CN113234160B (zh) * 2021-05-26 2022-05-27 广州爱思迈生物医药科技有限公司 一种抗pd-1抗体及其应用
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CN114159557B (zh) * 2021-11-09 2024-07-19 北京东方百泰生物科技股份有限公司 一种治疗肿瘤疾病的联合用药组合物及应用
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114539407B (zh) * 2021-12-31 2023-04-18 浙江大学 一种全人源抗PD-1的单克隆抗体No.1-10及其应用
CN114539406B (zh) * 2021-12-31 2023-04-14 浙江大学 一种全人源抗PD-1的单克隆抗体No.8-3及其应用
CN115925947B (zh) * 2022-09-27 2023-08-22 上海百英生物科技股份有限公司 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
CN117304327B (zh) * 2022-11-18 2024-04-05 上海百英生物科技股份有限公司 一种抗山羊IgG的兔单克隆抗体及其应用
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563193A (en) * 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ES2437327T3 (es) * 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
EP2262837A4 (en) * 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
BR112016005408B1 (pt) * 2013-09-13 2023-03-21 Beigene Switzerland Gmbh Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral
CN103525868B (zh) 2013-10-17 2015-01-21 百泰生物药业有限公司 哺乳动物细胞高效表达载体的构建及应用
CN104479020B (zh) * 2014-12-26 2019-08-02 上海复宏汉霖生物技术股份有限公司 一种抗pd-1人源抗体
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法

Also Published As

Publication number Publication date
BR112017010744A2 (zh) 2018-02-27
EA201792584A1 (ru) 2018-07-31
MX2017008662A (es) 2017-12-07
KR20170020933A (ko) 2017-02-24
NZ728874A (en) 2019-08-30
CN105061597B (zh) 2016-04-27
JP6588534B2 (ja) 2019-10-09
AR105619A1 (es) 2017-10-25
TW201643193A (zh) 2016-12-16
CA2972833A1 (en) 2016-12-15
EA036779B1 (ru) 2020-12-21
CN105061597A (zh) 2015-11-18
AU2015398193A1 (en) 2017-03-16
TWI659969B (zh) 2019-05-21
EP3176182A1 (en) 2017-06-07
KR101876689B1 (ko) 2018-08-02
EP3770177A1 (en) 2021-01-27
JP2017534247A (ja) 2017-11-24
EP3176182A4 (en) 2017-11-29
SG11201705252UA (en) 2017-07-28
AU2015398193B2 (en) 2018-10-25
WO2016197497A1 (zh) 2016-12-15
US20170240644A1 (en) 2017-08-24
CA2972833C (en) 2019-08-27

Similar Documents

Publication Publication Date Title
HK1215870A1 (zh) 種抗 的單克隆抗體及其獲得方法
HK1254880A1 (zh) 抗pd-1抗體及其應用
IL282403A (en) Antibodies against PD-1
HK1255195B (zh) Pd-1抗體
ZA201902265B (en) Anti-pd-1 antibodies and their uses
IL258214A (en) Antibodies - anti-pd-1 and preparations
ZA201803669B (en) Antibodies specifically binding pd-1 and their uses
IL257062A (en) New anti-pd-1 antibodies
IL251963A0 (en) Anti-1-pd antibodies
EP3356416A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF
GB201500319D0 (en) Anti-PD-L1 antibodies
ZA201901865B (en) Anti-pd-1 antibodies
ZA201800781B (en) Pd-1 antibodies
GB201419087D0 (en) Anti-PD-1 antibodies
GB201419080D0 (en) Anti-PD-1 antibodies